Oslo University Hospital Hf
- Address
- lock Available on a paid plan
Lipid‑lowering therapies
The Lipid Clinic at Oslo University Hospital Hf conducts research focused on cardiovascular diseases and nutritional and metabolic disorders, especially conditions driven by high triglycerides and cholesterol. Trials aim to test new agents that lower lipid levels, improve safety profiles, and potentially reduce heart‑related events.
- Olezarsen for severe hypertriglyceridemia and atherosclerotic disease
- Olpasiran targeting lipoprotein(a) to lower cardiovascular risk
- MK‑0616 oral therapy evaluating LDL‑C reduction
These studies bring together six investigators and seek to expand treatment options for patients with elevated triglycerides, high LDL‑C, and increased Lp(a) levels.
Acute hemorrhage management
In the realm of stroke and intracerebral bleeding, the site evaluates rapid‑acting drugs that may lower early mortality. The primary goal is to determine whether early administration improves survival within the first week after a bleed.
- Tranexamic acid safety and effect on early death after spontaneous ICH
By enrolling patients with hyperacute hemorrhage, the research team hopes to inform clinical practice on the use of antifibrinolytic therapy.
Genetic and atherosclerotic lipid disorders
Studies at the clinic also address inherited and plaque‑related conditions such as heterozygous familial hypercholesterolemia and extensive atherosclerosis. The objective is to assess how novel lipid‑targeting drugs influence disease progression and cardiovascular outcomes.
- Evaluating LDL‑C lowering efficacy in HeFH patients
- Measuring impact of Lp(a) reduction on coronary events in ASCVD
These investigations complement the broader effort to improve heart health for individuals with high‑risk lipid profiles.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1University Of Nottingham1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Ionis Pharmaceuticals Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Oslo University Hospital Hf
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial Hypercholesterolemia | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Sep 2023 | Apr 2025 |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isis 678354 Sodium Salt | 2 | Unknown | 2023-06-08 | 2023-07-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.